Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on August 21, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Planned modified Dutch auction tender offer to repurchase up to $230 million of common shares.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Planned modified Dutch auction tender offer to repurchase up to $230 million of common shares
- Proposed purchase price range of $5.00–$5.75 per share
- Potentially significant capital return and share-count reduction for remaining shareholders
- Tender offer not yet commenced, with final terms and conditions not assured
- Schedule TO and issuer bid circular expected upon commencement
Item EX-99.1 · Exhibit EX-99.1
- Planned $230M share repurchase via modified Dutch auction at $5.00–$5.75 per share
- Funding from cash on hand, returning proceeds from the Moderna settlement to shareholders
- Offer expected August 24–September 29, 2026, subject to exemptive regulatory relief
- Potentially reduces shares outstanding but may constrain cash available for clinical programs and litigation
- Moderna settlement proceeds and ongoing Pfizer/BioNTech enforcement support the capital-return strategy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.